Searchable abstracts of presentations at key conferences in endocrinology

ea0092op-12-01 | Oral Session 12: Emerging Insights into Thyroid Cancer Genetics | ETA2023

Prospective evaluation of thyrospec molecular testing of indeterminate thyroid nodule cytologies following diagnostic pathway optimization

Stewardson Paul , Eszlinger Markus , Wu Jiahui , Khalil Moosa , J Demetrick Douglas , Cheung Winson , Box Adrian , Paschke Ralf

Objectives: Molecular diagnostic tests for indeterminate thyroid nodules (ITNs) are marketed based on negative predictive value (NPV) and benign call rate. Arguments that unnecessary surgeries are avoided based on NPV/BCR incorrectly assume that all ITNs would undergo diagnostic surgery in the absence of molecular testing. In our practice with centralized triage and cytopathology the resection and malignancy rate, respectively, were 21% and 26% for AUS/FLUS and 56% and 43% for...

ea0098t11 | Trials In Progress | NANETS2023

NET RETREAT: a Phase II Study of 177Lutetium-Dotatate Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET

Chauhan Aman , O'Callaghan Chris , Myrehaug Sten , Bodei Lisa , Kunz Pamela , Dasari Arvind , Strosberg Jonathan , Alexander Stefanie , Cheung Winson , Singh Simron

Background: 177Lu-DOTATATE is an FDA and Health Canada-approved treatment option for metastatic, progressive GEPNET patients. 177Lu-DOTATATE is now often considered the treatment of choice for small bowel/midgut patients who have progressed on somatostatin analogs (SSA). Despite 177Lu- DOTATATE’s impressive disease stabilization, many patients will eventually progress. Progression after prior use of PRRT does not necessarily render these tumors resistant to future PRRT tr...